3:20cv1828 • September 16, 2020
Class Period Start
December 6, 2017
Class Period End
June 23, 2021
PSLRA Deadline
November 16, 2020
Case Allegations
10b5
Statutes of Repose
Dec 6, 2020
Country
United States
Court
Federal Court
Please note that for cases in the settlement stage, claims are handled by the claims administrator and NOT Levi & Korsinsky. Any information or documentation previously provided to us does not constitute submission of a claim. If you need to file a claim, check the status of a claim, or have questions regarding distribution of settlement funds, please contact the claims administrator below.
Claim Deadline
May 2, 2022
Settlement Fund
$12,750,000
Settlement Status
Disbursed
Settlement Class
All persons or entities that purchased, or otherwise acquired, the stock of Odonate Therapeutics, Inc. (“Odonate”) (NASDAQ: ODT) between December 7, 2017 and March 25, 2021, both dates inclusive.
Claim Administrator
Strategic Claims Services
Kendall v. Odonate Therapeutics, Inc. c/o Strategic Claims Services
600 North Jackson Street, Suite 205 Media, PA 19063
+1 866-274-4004
[email protected]
Settlement Website
www.strategicclaims.net/odonateHearing Date
June 6, 2022
Opt-out Deadline
May 2, 2022
Settlement Note
Download hereProof Of Claim
Download here
Oct 11, 2022
The court has approved the distribution of settlement funds to eligible class members. Investors with approved claims may receive payments from the settlement. If you have questions about your claim or payment, contact the claims administrator.
Jun 6, 2022
The court has granted final approval of the settlement. Eligible investors who submit valid claims may receive a payment once the claims review and distribution process is completed.
Jan 18, 2022
To receive your portion of the recovery (if you are eligible), you must submit this form to the claims administrator by the deadline indicated on the form itself. If you do not submit this form in time, you will not be entitled to compensation. If you have questions about how to complete the form, you should contact the claims administrator.
Jan 11, 2022
Preliminary Approval of Settlement
The court has granted preliminary approval of a proposed settlement. This means the settlement can move forward for further consideration, but it has not yet received final approval. Potential class members will generally receive notice explaining the settlement, their rights, and any deadlines for submitting a claim, objecting to the settlement, or choosing not to participate.
Dec 3, 2021
Oct 27, 2021
Aug 4, 2021
The court has denied the defendants' request to dismiss the lawsuit. The case can now move forward to the next stage of litigation.
Jun 21, 2021
May 13, 2021
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Apr 13, 2021
A new complaint has been filed on behalf of certain investors in Odonate Therapeutics, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Mar 25, 2021
Feb 16, 2021
A new complaint has been filed on behalf of certain investors in Odonate Therapeutics, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Dec 28, 2020
Dec 14, 2020
The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.
Nov 24, 2020
Sep 16, 2020
A securities fraud class action complaint has been filed on behalf of certain investors in Odonate Therapeutics, Inc..
TOP
